AKT1 and hepatocellular carcinoma: In the current study, treatment with either the Akt inhibitor MK2206 or Akt-specific siRNA led to down-regulation of NF-κB expression in HCC cells; intriguingly, treatment with either the NF-κB inhibitor Bay11-7082 or NF-κB siRNA also led to down-regulation of the expressions of TrkB and pAkt, and this process was accompanied by abrogation of midkine-induced anoikis resistance.